Waldencast plc (NASDAQ:WALD) is a skincare company known for its advanced treatments targeting skin aging, damage, and other concerns. Founded in 1988 and based in White Plains, New York, Waldencast offers products through dermatologists and skincare professionals. Its portfolio includes Obagi Medical and Obagi Clinical, which focus on enhancing skin tone and texture.
The consensus price target for Waldencast has decreased from $4.80 a year ago to $3.25 in recent months. This decline suggests analysts have become more cautious about the company's stock performance. Despite this, D.A. Davidson has set a higher price target of $15.50, indicating differing opinions among analysts. Waldencast faces challenges such as margin pressure and negative earnings due to high selling, general, and administrative expenses, and significant debt. However, the company maintains solid revenue growth. In Q1 2025, Waldencast reported a net revenue of $65.4 million, a 4.1% decline from the previous year, but achieved an adjusted gross margin of 76.4%.
The company's financial profile is typical for a high-growth firm, with negative cash flow and high leverage. Despite these challenges, Waldencast has manageable liquidity and a long debt runway until 2030. The company's Q4 2024 results showed a net revenue of $72.1 million, a 29.4% growth, and an adjusted EBITDA of $11.2 million, doubling from Q4 2023. Waldencast's recent earnings calls have provided insights into its financial performance and strategic initiatives. Analysts from firms like Alliance Global Partners and TD Cowen participated in these calls, highlighting the company's ongoing efforts to navigate market challenges and capitalize on growth opportunities.
